BR9915218A - Protein composition of fusion, recombinant lysozyme and method of prophylaxis or therapeutic treatment of bacterial infection in mammals - Google Patents
Protein composition of fusion, recombinant lysozyme and method of prophylaxis or therapeutic treatment of bacterial infection in mammalsInfo
- Publication number
- BR9915218A BR9915218A BR9915218-5A BR9915218A BR9915218A BR 9915218 A BR9915218 A BR 9915218A BR 9915218 A BR9915218 A BR 9915218A BR 9915218 A BR9915218 A BR 9915218A
- Authority
- BR
- Brazil
- Prior art keywords
- prophylaxis
- therapeutic treatment
- lysozyme
- recombinant lysozyme
- composition
- Prior art date
Links
- 102000016943 Muramidase Human genes 0.000 title abstract 5
- 108010014251 Muramidase Proteins 0.000 title abstract 5
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 title abstract 5
- 229960000274 lysozyme Drugs 0.000 title abstract 5
- 235000010335 lysozyme Nutrition 0.000 title abstract 5
- 239000004325 lysozyme Substances 0.000 title abstract 5
- 208000035143 Bacterial infection Diseases 0.000 title abstract 4
- 208000022362 bacterial infectious disease Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 238000011282 treatment Methods 0.000 title abstract 4
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 230000001225 therapeutic effect Effects 0.000 title abstract 3
- 241000124008 Mammalia Species 0.000 title 1
- 230000004927 fusion Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 101001086862 Homo sapiens Pulmonary surfactant-associated protein B Proteins 0.000 abstract 3
- 102100032617 Pulmonary surfactant-associated protein B Human genes 0.000 abstract 3
- 230000003115 biocidal effect Effects 0.000 abstract 2
- 102000037865 fusion proteins Human genes 0.000 abstract 2
- 108020001507 fusion proteins Proteins 0.000 abstract 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C12N9/2462—Lysozyme (3.2.1.17)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
<B>COMPOSIçãO, PROTEìNA DE FUSãO, LISOZIMA RECOMBINANTE E MéTODO DE PROFILAXIA OU TRATAMENTO TERAPêUTICO DE INFECçãO BACTERIANA EM MAMìFERO<D> Método e composição para a profilaxia e/ou tratamento terapêutico de infecções bacterianas, particularmente infecções bacterianas respiratórias. Uma proteína de fusão da lisozima e o propéptido terminal carboxílio da proteína tensioativa B (SP-B) com os precedentes dez aminoácidos do péptido SP-B maduro ou a lisozima recombinante sozinha é administrada num meio farmaceuticamente aceitável a um indivíduo. A proteína de fusão ou a lisozima recombinante podem ser selecionadas de forma a serem supridas a um ponto de infecção alvo, tal como os pulmões ou trato gastrintestinal. O método e composição eliminam problemas associados aos tratamentos antibióticos convencionais, tais como ineficácia e promoção de cepas bacterianas resistentes aos antibióticos.<B> COMPOSITION, FUSION PROTEIN, RECOMBINANT LYSOZYME AND METHOD OF PROPHYLAXIS OR THERAPEUTIC TREATMENT OF BACTERIAL INFECTION IN MAMMALIAN <D> Method and composition for the prophylaxis and / or therapeutic treatment of bacterial infections, particularly respiratory bacterial infections. A lysozyme fusion protein and the carboxyl terminal propeptide of the surfactant protein B (SP-B) with the preceding ten amino acids of the mature SP-B peptide or the recombinant lysozyme alone is administered in a pharmaceutically acceptable medium to an individual. The fusion protein or recombinant lysozyme can be selected to be delivered to a target point of infection, such as the lungs or gastrointestinal tract. The method and composition eliminate problems associated with conventional antibiotic treatments, such as inefficiency and promotion of antibiotic-resistant bacterial strains.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/193,877 US5993809A (en) | 1998-11-18 | 1998-11-18 | Lysozyme fusion proteins in infections |
| US44074299A | 1999-11-16 | 1999-11-16 | |
| PCT/US1999/027403 WO2000029588A1 (en) | 1998-11-18 | 1999-11-18 | Lysozyme fusion proteins in infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9915218A true BR9915218A (en) | 2001-07-31 |
Family
ID=26889453
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9915218-5A BR9915218A (en) | 1998-11-18 | 1999-11-18 | Protein composition of fusion, recombinant lysozyme and method of prophylaxis or therapeutic treatment of bacterial infection in mammals |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1129201A1 (en) |
| JP (1) | JP2002530083A (en) |
| AU (1) | AU759743B2 (en) |
| BR (1) | BR9915218A (en) |
| CA (1) | CA2349837A1 (en) |
| WO (1) | WO2000029588A1 (en) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001000855A1 (en) * | 1999-06-23 | 2001-01-04 | Ppl Therapeutics (Scotland) Ltd. | Fusion proteins incorporating lysozyme |
| CA2588965C (en) | 2003-12-18 | 2013-01-22 | Werner Seeger | Novel chimeric plasminogen activators and their pharmaceutical use |
| WO2005108563A2 (en) * | 2004-04-19 | 2005-11-17 | University Of Chicago | Peptidoglycan-hydrolyzing protein encoded by bacteriophage n4 |
| KR20070101356A (en) * | 2005-01-27 | 2007-10-16 | 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 | A method for characterizing the efficacy of an agent targeting a primary cystic fibrosis defect |
| CN103635584B (en) * | 2011-04-12 | 2017-10-27 | 冈戈根股份有限公司 | chimeric antibacterial polypeptide |
| CN104817616A (en) * | 2014-01-30 | 2015-08-05 | 陈光健 | Oligopeptide CD02, and preparation method and application thereof |
| CN104817618B (en) * | 2014-01-30 | 2018-07-03 | 陈光健 | Oligopeptides CD01 and its preparation method and application |
| CN114149986B (en) * | 2022-02-08 | 2022-05-06 | 中国科学院天津工业生物技术研究所 | Bacillus licheniformis lysozyme mutant and application thereof in preservation of rainbow trout |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3540075A1 (en) * | 1985-11-12 | 1987-05-14 | Boehringer Ingelheim Int | HUMAN LYSOZYM |
| DE3818094C1 (en) * | 1988-05-27 | 1989-07-20 | Medichemie Ag, Ettingen, Ch | |
| US5006343A (en) * | 1988-12-29 | 1991-04-09 | Benson Bradley J | Pulmonary administration of pharmaceutically active substances |
-
1999
- 1999-11-18 BR BR9915218-5A patent/BR9915218A/en not_active IP Right Cessation
- 1999-11-18 CA CA002349837A patent/CA2349837A1/en not_active Abandoned
- 1999-11-18 AU AU23459/00A patent/AU759743B2/en not_active Ceased
- 1999-11-18 EP EP99967112A patent/EP1129201A1/en not_active Withdrawn
- 1999-11-18 JP JP2000582571A patent/JP2002530083A/en active Pending
- 1999-11-18 WO PCT/US1999/027403 patent/WO2000029588A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002530083A (en) | 2002-09-17 |
| AU2345900A (en) | 2000-06-05 |
| EP1129201A1 (en) | 2001-09-05 |
| AU759743B2 (en) | 2003-05-01 |
| CA2349837A1 (en) | 2000-05-25 |
| WO2000029588A1 (en) | 2000-05-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | OM‐LV20, a novel peptide from odorous frog skin, accelerates wound healing in vitro and in vivo | |
| BR0012200B1 (en) | peptide composition for treating sexual dysfunction and pharmaceutical composition for treating sexual dysfunction in a mammal. | |
| US20040106564A1 (en) | Use of slpi for treating chronic inflammatory intestinal diseases | |
| BR9915218A (en) | Protein composition of fusion, recombinant lysozyme and method of prophylaxis or therapeutic treatment of bacterial infection in mammals | |
| JP2008526935A5 (en) | ||
| SE9804614A0 (en) | New peptides and use thereof | |
| IL210455A (en) | Polypeptide for reducing il13 signaling in a mammal and use of the polypeptide for the manufacture of a medicament for up-regulating il-13ra2 gene expression in a mammal | |
| CA2308116A1 (en) | Low-toxicity human interferon-alpha analog | |
| JP2002541066A (en) | Antimicrobial / Endotoxin neutralizing polypeptide | |
| US20190337997A1 (en) | Modified peptides | |
| WO1994028921A1 (en) | Method of treating pulmonary disease states with non-naturally occurring amphipathic peptides | |
| BRPI0012265B8 (en) | modified human granulocyte colony stimulating factor and process to produce the same | |
| GB1077136A (en) | Medicament for affections of mucous membranes | |
| RU2005127076A (en) | PEPTIDE TOXIN INHIBITORS, DERIVATIVES LL-37 | |
| NZ526879A (en) | Genes and proteins, and their use | |
| US8815812B2 (en) | Synthetic arginine substituted peptides and their use | |
| US6413510B1 (en) | Dimeric modified groβ protein | |
| WO2013009103A2 (en) | Recombinant microorganism which secretes egf via an abc transporter, and composition for alleviating or treating peptic ulcers comprising same as an active ingredient | |
| Meads et al. | Penicillin treatment of scarlet fever: bacteriologic study of the nose and throat of patients treated intramuscularly or by spray with penicillin and a comparison with sulfadiazine | |
| EP1602375A3 (en) | Administration of products of the 5-lipoxygenase pathway for treating microbial infections | |
| Banu et al. | Defensins: Therapeutic molecules with potential to treat SARS-CoV-2 infection | |
| CN114957394B (en) | Polypeptide PM-7 for promoting skin repair and application thereof | |
| WO2000040204A9 (en) | Methods for treating cystic fibrosis | |
| WO2022072550A3 (en) | Clec2 fusion protein and uses thereof | |
| WO2003064446A3 (en) | Plasma protein-binding peptides from bacterial curli |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AO NAO RECOLHIMENTO DA 8A E 9A ANUIDADE(S). |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DE RPI 1999 DE 28/04/2009. |